All News

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

ACC.24: Zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB; SQ dosing is every 3-6 months.

ACC.24: Individuals with ASCVD not at target LDL-C on maximum statin therapy need immediate intervention and one that works, said V-INITIATE primary investigator.

ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.

ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.

ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.

Your daily dose of the clinical news you may have missed.

In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.

The end of another quarter means a new list of FDA-approved drugs for conditions treated in primary care. Are you up-to-date? Click through to find out.

The program, when implemented with support of resident training and tangible tools, reduced parent-reported injuries throughout the first 2 years of life.

Your daily dose of the clinical news you may have missed.

Migraine was the most important nontraditional risk factor linked to stroke in adults aged 18 to 34 years and should be considered in evaluation for an event.

Positive findings from a repeat dosing study of neffy under nasal allergen challenge conditions will support a potential PDUFA date of October 2, 2024, the company said.

The Low EF AI is designed to detect low ejection fraction in 15 seconds during a primary care exam.

The quality performance measure is viable and reliable and could help improve early CRC detection rates via timely colonoscopy following abnormal stool-based test.

Your daily dose of the clinical news you may have missed.

Atogepant was associated with fewer monthly migraine days, fewer acute medication use days, and greater QoL compared with rimegepant after 12 weeks.

ACC.24: Data showed that individuals who used e-cigarettes were approximately 19% more likely to develop heart failure compared with those who had never vaped.